A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT02873962
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    * Bevacizumab will be given intravenously at a pre-determined dosage * One dose reduction will be allowed for Bevacizumab
  • Nivolumab — DRUG
    * Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage. * No dose reductions or escalations will be allowed for Nivolumab
  • Rucaparib — DRUG
    * Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage. * Up to three dose reductions will be allowed for Rucaparib (depending on cohort).

Study Details

This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Key Dates

Start date
Nov 10, 2016
Status verified
Mar 2026
Primary completion
Feb 28, 2025
Completion
Jan 31, 2027

Study Design

Enrollment
72 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Nivolumab with Bevacizumab
    Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
  • Experimental: Cohort 2: Nivolumab with Bevacizumab and Rucaparib
    Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
  • Experimental: Cohort 3: Nivolumab with Bevacizumab and Rucaparib
    Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .

Primary Outcome Measure

Cohort 1: Objective Response Rate [ Time Frame: 18 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Dana Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02114-

Related coverage on Hipa.ai

Find similar trials in Boston, MA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Beth Israel Deaconess Medical Center· Boston, MADana Farber Cancer Institute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies